Penbrook Management LLC Cuts Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Penbrook Management LLC lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 39.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,115 shares of the medical instruments supplier’s stock after selling 724 shares during the period. Penbrook Management LLC’s holdings in Becton, Dickinson and Company were worth $276,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Livelsberger Financial Advisory bought a new stake in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $27,000. OLD Point Trust & Financial Services N A purchased a new stake in shares of Becton, Dickinson and Company during the fourth quarter valued at $29,000. DiNuzzo Private Wealth Inc. purchased a new position in Becton, Dickinson and Company in the 4th quarter worth about $30,000. Scarborough Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at about $32,000. Finally, Fortitude Family Office LLC purchased a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $35,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of research reports. The Goldman Sachs Group assumed coverage on Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 price target on the stock. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 27th. Barclays boosted their target price on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a report on Monday, May 6th. Finally, Evercore ISI cut their target price on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $280.86.

Becton, Dickinson and Company Trading Down 0.0 %

BDX traded down $0.03 during trading on Tuesday, reaching $229.24. The company had a trading volume of 662,939 shares, compared to its average volume of 1,444,290. The company has a quick ratio of 0.97, a current ratio of 1.41 and a debt-to-equity ratio of 0.62. The stock has a market cap of $66.25 billion, a P/E ratio of 50.45, a PEG ratio of 2.05 and a beta of 0.42. Becton, Dickinson and Company has a 52 week low of $224.00 and a 52 week high of $287.32. The business has a 50 day simple moving average of $234.27 and a 200-day simple moving average of $237.76.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. The company had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter last year, the business posted $2.86 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 28th. Shareholders of record on Monday, June 10th were given a dividend of $0.95 per share. The ex-dividend date of this dividend was Monday, June 10th. This represents a $3.80 annualized dividend and a yield of 1.66%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Insider Activity at Becton, Dickinson and Company

In related news, SVP Thomas J. Spoerel sold 300 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the sale, the senior vice president now owns 1,976 shares of the company’s stock, valued at $472,876.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Roland Goette sold 3,300 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $236.70, for a total value of $781,110.00. Following the completion of the transaction, the executive vice president now directly owns 14,608 shares in the company, valued at $3,457,713.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Thomas J. Spoerel sold 300 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the sale, the senior vice president now owns 1,976 shares of the company’s stock, valued at $472,876.56. The disclosure for this sale can be found here. Insiders have sold a total of 8,615 shares of company stock valued at $2,033,381 over the last quarter. 0.31% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.